

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.  
QA0253 NP  
APPLICATION NO.  
10/702,295  
APPLICANT  
BARBOSA ET AL.  
FILING DATE  
NOVEMBER 6, 2003

Group



U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
BC	AA	5,212,291	5/18/93	Murdock et al.	536	6.4	
BC	AB	5,527,896	6/18/96	Wigler et al.	536	23.5	
BC	AC	5,726,302	3/10/98	Ugarkar et al.	536	27.13	
BC	AD	5,733,913	3/31/98	Blankley et al.	514	264.11	
BC	AE	5,733,914	3/31/98	Blankley et al.	514	264.11	
BC	AF	5,977,305	11/2/99	Wigler et al.	530	350	
BC	AG	6,028,183	2/22/00	Lin et al.	536	22.1	
	AH						
	AI						
	AJ						
	AK						
	AL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
BC	AM	EP 0 767 172	4/9/97	EP	—	—	<input type="checkbox"/>	<input type="checkbox"/>
BC	AN	EP 0 861 836	9/2/98	EP	—	—	<input type="checkbox"/>	<input type="checkbox"/>
BC	AO	EP 1 201 765	5/2/00	EP	—	—	<input type="checkbox"/>	<input type="checkbox"/>
** BC	AP	ES 2 009 145	9/1/89	ES	—	—	<input type="checkbox"/>	<input type="checkbox"/>
** BC	AQ	JP 58-150503	9/7/83	JP	—	—	<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

BC	AR	Han, P. et al., "Alternative Splicing of the High Affinity cAMP-Specific Phosphodiesterase (PDE7A) mRNA in Human Skeletal Muscle and Heart", The Journal of Biological Chemistry, Vol. 272, No. 26, pp. 16152-16157 (1997)
BC	AS	Henry, J.R. et al., "p38 mitogen-activated protein kinase as a target for drug discovery", Drugs of the Future, Vol. 24, No. 12, pp. 1345-1354 (1999)
BC	AT	Li, L. et al., "CD3- and CD28-Dependent Induction of PDE7 Required for T Cell Activation", Science, Vol. 283, pp. 848-851 (1999)

EXAMINER Brenda Coleman DATE CONSIDERED March 13, 2006

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

\*\* structures only

**INFORMATION DISCLOSURE CITATION**

(Use several sheets if necessary)

Sheet 2 of 3

ATTY. DOCKET NO.  
QA0253 NP  
APPLICATION NO.  
10/702,295  
APPLICANT  
BARBOSA ET AL  
FILING DATE  
NOVEMBER 6, 2003

Group

**FOREIGN PATENT DOCUMENTS**

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLAS S	TRANSLATION	
							YES	NO
BC	2AA	WO 98/13350	4/2/98	PCT	—	—	<input type="checkbox"/>	<input type="checkbox"/>
BC	2AB	WO 98/33798	8/6/98	PCT	—	—	<input type="checkbox"/>	<input type="checkbox"/>
BC	2AC	WO 01/28987	4/26/01	PCT	—	—	<input type="checkbox"/>	<input type="checkbox"/>
BC	2AD	WO 01/44258	6/21/01	PCT	—	—	<input type="checkbox"/>	<input type="checkbox"/>
BC	2AE	WO 01/55148	8/2/01	PCT	—	—	<input type="checkbox"/>	<input type="checkbox"/>
BC	2AF	WO 01/64679	9/7/01	PCT	—	—	<input type="checkbox"/>	<input type="checkbox"/>
	AG						<input type="checkbox"/>	<input type="checkbox"/>
	AH						<input type="checkbox"/>	<input type="checkbox"/>
	AI						<input type="checkbox"/>	<input type="checkbox"/>
	AJ						<input type="checkbox"/>	<input type="checkbox"/>
	AK						<input type="checkbox"/>	<input type="checkbox"/>
	AL						<input type="checkbox"/>	<input type="checkbox"/>
	AM						<input type="checkbox"/>	<input type="checkbox"/>
	AN						<input type="checkbox"/>	<input type="checkbox"/>
	AO						<input type="checkbox"/>	<input type="checkbox"/>
	AP						<input type="checkbox"/>	<input type="checkbox"/>
	AQ						<input type="checkbox"/>	<input type="checkbox"/>
	AR						<input type="checkbox"/>	<input type="checkbox"/>
	AS						<input type="checkbox"/>	<input type="checkbox"/>
	AT						<input type="checkbox"/>	<input type="checkbox"/>
	AU						<input type="checkbox"/>	<input type="checkbox"/>
	AV						<input type="checkbox"/>	<input type="checkbox"/>
	AW						<input type="checkbox"/>	<input type="checkbox"/>
	AX						<input type="checkbox"/>	<input type="checkbox"/>
	AY						<input type="checkbox"/>	<input type="checkbox"/>
	AZ						<input type="checkbox"/>	<input type="checkbox"/>

EXAMINER

*Brenda Coleman*

DATE CONSIDERED

*March 13, 2006*

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

**INFORMATION DISCLOSURE CITATION**

(Use several sheets if necessary)

ATTY. DOCKET NO.  
QA0253 NP  
APPLICATION NO.  
10/702,295  
APPLICANT  
BARBOSA ET AL.  
FILING DATE  
NOVEMBER 6, 2003

Sheet 3 of 3

Group

**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent pages, Etc.)

BC	3AA	Moreland, L.W. et al., "Etanercept Therapy in Rheumatoid Arthritis: A Randomized, Controlled Trial", Ann. Intern. Med., Vol. 130, pp. 478-486 (1999)
BC	3AB	Nakata, A. et al., "Potential role of phosphodiesterase 7 in human T cell function: comparative effects of two phosphodiesterase inhibitors", Clin. Exp. Immunol., Vol. 128, pp. 460-466 (2002)
BC	3AC	Rankin, E.C.C. et al., "The Therapeutic Effects of an Engineered Human Anti-Tumor Necrosis Factor Alpha Antibody (CDP571) in Rheumatoid Arthritis", British Journal of Rheumatology, Vol. 34, pp. 334-342 (1995)
BC	3AD	Salituro, F.G. et al., "Inhibitors of p38 MAP Kinase: Therapeutic Intervention in Cytokine-Mediated Diseases", Current Medicinal Chemistry, Vol. 6, pp. 807-823 (1999)
BC	3AE	Sasaki, T. et al., "Identification of Human PDE7B, a cAMP-Specific Phosphodiesterase", Biochemical and Biophysical Research Communications, Vol. 271, pp. 575-583 (2000)
	AF	
	AG	
	AH	
	AI	
	AJ	
	AK	
	AL	
	AM	
	AN	

EXAMINER

*Brenda Colarian*

DATE CONSIDERED

*March 13, 2006*

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.